BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test on May 19, 2026 BioMarin BMN Clinical Benefit Deficiency ENPP1 gene growth Z-score Hereditary Diseases Infrequent inorganic pyrophosphate Plasma prepulse inhibition activity Rare Diseases RGI-C scores Rickets Severities +